Artelo biosciences announces $1.425 million at-the-market private placement financing

Solana beach, calif., june 26, 2025 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced it has entered into a definitive securities purchase agreement for an at-the-market private placement for gross proceeds of approximately $1.425 million.
ARTL Ratings Summary
ARTL Quant Ranking